2024-03-29T05:03:01Zhttp://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/90562021-06-23T09:49:07Zcom_10324_1133com_10324_931com_10324_894col_10324_1209
00925njm 22002777a 4500
dc
Carvajal García-Pando, Alfonso
author
Macías, Diego
author
Sáinz Gil, María
author
Ortega, Sara
author
Martín Arias, Luis Hermenegildo
author
Velasco Martín, Alfonso
author
Bagheri, Haleh
author
Lapeyre-Mestre, Maryse
author
Montastruc, Jean Louis
author
2006
Objective: HMG CoA Reductase inhibitors, more commonly called statins, are
used in the pharmacological management of hyperlipidaemia. At present, the use
of these drugs is increasing worldwide. They have been linked to certain adverse
drug reactions, including impotence. The aim of the present study is to explore the
basis of the association between statin use and impotence using data from
spontaneous reports.
Method: We analysed the cases of impotence associated with statins that were
collected by the Spanish and French pharmacovigilance systems. We used cases
of impotence as a numerator and consumption data as a denominator to estimate
the cumulative reported incidence of impotence.
Results: Thirty-eight cases of impotence associated with statins have been
identified in the database of the Spanish pharmacovigilance system; overall, there
was a temporal sequence of events in all cases and the adverse reaction disappeared
after drug withdrawal in 93% of the cases. Sixteen patients had also been
treated with other drugs. In France, 37 cases were collected. In 85% of these cases
recovery from the adverse reaction was observed after drug withdrawal; there was
a positive rechallenge in five cases, and 15 patients were receiving other drugs at
the same time. No significant differences among reported incidences with different
statins were found.
Conclusion: Considering the widespread use of this drug class and the under-reporting
of this particular reaction it could affect a large number of patients. The
reaction seems to be reversible in most of the cases after drug withdrawal. Doctors
should be aware of this potential adverse reaction when prescribing statins to their
patients.
Drug Safety, 2006; 29 (2): 143-149
0114-5916
http://uvadoc.uva.es/handle/10324/9056
10.2165/00002018-200629020-00004
143
2
149
Drug Safety
29
Medicamentos - Efectos secundarios
Impotencia sexual
HMG CoA Reductase Inhibitors and Impotence Two Case Series from the Spanish and French Drug Monitoring Systems